KAIYUE INTERNATIONAL INC.

Condensed Interim Financial Statements

(Expressed in Canadian Dollars)

(Unaudited)

For the Three and Nine Months Ended September 30, 2017 and 2016

Contents

Notice of No Review of Condensed Interim Financial Statements

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the condensed interim financial statements; they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditors have not performed a review of these condensed interim financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

Kaiyue International Inc.
Condensed Interim Statements of Financial Position
(Expressed in Canadian dollars)

	Notes	September 30, 2017 (Unaudited) $	December 31, 2016 (Audited) $
Assets			
Current Assets			
Cash and cash equivalents		200,552	87,660
GST receivable		2,348	1,277
Prepaid expenses		6,125	4,288
		209,025	**93,225**
Total Assets		**209,025**	**93,225**
Liabilities and Equity			
Current Liabilities			
Trade payables and accrued liabilities		22,699	1,382
Due to related parties	5	16,500	19,950
		39,199	**21,332**
Equity			
Share capital	8	2,175,070	1,881,741
Contributed surplus		26,495	25,952
Deficit		(2,031,739)	(1,835,800)
		169,826	**71,893**
Total Liabilities and Equity		**209,025**	**93,225**

Subsequent Event - Note 9

Approved on behalf of the Board of Directors:

"Ping (Johnson) Zhang", Director *"George Dorin"*, Director

The accompanying notes form an integral part of these condensed interim financial statements

Kaiyue International Inc.
Condensed Interim Statements of Operations and Comprehensive Loss
(Expressed in Canadian dollars)
(Unaudited)

		Three Months Ended		Nine Months Ended	
	Notes	**September 30, 2017**	**September 30, 2016**	**September 30, 2017**	**September 30, 2016**
		$	**$**	**$**	**$**
Expenses					
Bank charges		302	197	1,071	753
Consulting fees	5	22,500	22,500	67,500	67,500
Director fees	5	2,200	2,200	6,600	6,600
Filing fees		-	1,679	9,321	6,879
Insurance		1,838	1,808	5,513	5,308
General admin expenses		3,169	5,655	13,121	13,825
Professional fees		12,200	2,394	25,989	12,594
Rent	5	16,500	16,500	49,500	49,500
Salaries and wages		-	-	-	6,455
Share-based payment	5	-	355	543	1,793
Travel expense		2,937	492	16,781	11,914
		61,646	53,780	195,939	183,121
Net loss and comprehensive loss for the period		**61,646**	**53,780**	**195,939**	**183,121**
Loss per ordinary share:					
Basic and Diluted		$ (0.00)	$ (0.00)	$ (0.01)	$ (0.01)
Weighted average number of ordinary shares outstanding:					
Basic and diluted		21,174,230	15,174,230	19,502,069	15,174,230

The accompanying notes form an integral part of these condensed interim financial statements

Kaiyue International Inc.
Condensed Interim Statements of Changes in Equity
(Expressed in Canadian dollars)
(Unaudited)

	Shares	Share capital $	Contributed Surplus $	Deficit $	Total $
Balance at December 31, 2015	15,274,230	1,881,741	23,806	(1,604,060)	301,487
Share-based payment	-	-	1,793	-	1,793
Net loss for the period	-	-	-	(183,121)	(183,121)
Balance at September 30, 2016	15,274,230	1,880,741	25,599	(1,787,181)	120,159
Balance at December 31, 2016	15,274,230	1,881,741	25,952	(1,835,800)	71,893
Shares issued for cash private placement	5,900,000	295,000	-	-	295,000
Share issuance costs	-	(1,671)	-	-	(1,671)
Share-based payment	-	-	543	-	543
Net loss for the period	-	-	-	(195,939)	(195,939)
Balance at September 30, 2017	21,174,230	2,175,070	26,495	(2,031,739)	169,826

The accompanying notes form an integral part of these condensed interim financial statements

Kaiyue International Inc.
Condensed Interim Statements of Cash Flows
(Expressed in Canadian dollars)
(Unaudited)

	For the nine months ended September 30,	
	2017 **$**	**2016** **$**
Operating activities		
Net loss for the period	(195,939)	(183,121)
Item not involving cash		
Share-based payment	543	1,793
Changes in non-cash working capital balances:		
GST receivable	(1,071)	5,072
Prepaid expenses	(1,837)	(2,042)
Trade payables and accrued liabilities	21,317	(8,779)
Net cash (used in) operating activities	**(176,987)**	**(187,077)**
Financing activity		
Due to related parties	(3,450)	8,961
Share issued for cash	295,000	-
Share issuance costs paid in cash	(1,671)	-
Net cash provided by financing activity	**289,879**	**8,961**
Net increase (decrease) in cash and cash equivalents during the period	**112,892**	**(178,116)**
Cash at beginning of period	**87,660**	**316,093**
Cash at end of period	**200,552**	**137,977**

The accompanying notes form an integral part of these condensed interim financial statements

1. NATURE OF OPERATIONS AND GOING CONCERN

Kaiyue International Inc. ("Kaiyue" or the "Company") was incorporated under the Business Corporation Act of Alberta on November 23, 2009. The Company trades under the symbol KYU.V on the TSX Venture (the "Exchange"). The principal address and registered and records office of the Company is located at 3500, 855 – 2 Street SW, Calgary, Alberta, Canada. The Company is an exploration stage public company whose principal business activities are the acquisition and exploration of mineral properties. Its shares are listed on the TSX Venture Exchange under the symbol KYU (See-Note 9).

These condensed interim financial statements have been prepared using International Financial Reporting Standards ("IFRS") applicable to a "going concern", which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. Management is of the opinion that the funds available at the end of the period will allow the Company to meet its current ongoing obligations and future contractual commitments for at least the next twelve months. As at September 30, 2017, the Company had working capital of $169,826 (December 31, 2016 - $71,893). The Company did not generate revenue nor cash flows from its operations to date and has a cumulated deficit of $2,031,739 (December 31, 2016 - $1,835,800). Beyond the twelve month period, the Company will require additional financing or other sources of funding, which if not raised, would result in the curtailment of activities. As a result, there is a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern and accordingly use accounting principles applicable to a going concern.

To date, the Company has raised funds principally through the issuance of shares. In the foreseeable future, the Company will likely remain dependent on the issuance of shares, obtaining additional financing from shareholders, receiving continued financial support from related parties and creditors, or generating profitable operations. The Company continues to minimize uncommitted capital expenditures and exploration expenditures in order to preserve the Company's financial resources.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

a) Statement of compliance

The condensed interim financial statements (the "interim financial statements") have been prepared in accordance with International Financial Reporting standards ("IFRS") applicable to the preparation of interim financial statements, including International Accounting Standard 34, Interim Financial Reporting ("IAS 34") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC" and "SIC") adopted by the International Accounting Standards Board ("IASB").

The interim financial statements of the Company for the nine months ended September 30, 2017 were reviewed by the Audit Committee and approved and authorized for issuance by the Board of Directors on November 28, 2017.

b) Basis of preparation

The preparation of these interim financial statements requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the interim financial statements, are disclosed in Note 4. Actual results may differ from these estimates.

The interim financial statements are presented in Canadian dollars, which is the Company's functional currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the date of the transactions. At periods end, foreign currency denominated monetary assets and liabilities are translated to the functional currency using the prevailing rate of exchange at the statement of financial position date. Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items at periods end exchange rates are recognized in profit and loss.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED

c) Change in accounting policies

The accounting policies applied in preparation of these condensed interim consolidated financial statements are consistent with those applied and disclosed in the Company's financial statements for the year ended December 31, 2016. The Company did not adopted any accounting policies effective January 1, 2017 that would have a material impact on these interim financial statements.

3. ACCOUNTING STANDARDS ISSUED BUT NOT YET EFFECTIVE

Standards issued but not yet effective up to the date of issuance of the Company's financial statements are listed below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they become effective. The Company does not expect the impact of such changes on the financial statements to be material.

- IFRS 9 Financial Instruments

  In July 2014, the IASB issued IFRS 9, Financial Instruments, will replace IAS 39, Financial Instruments: Recognition and Measurement, and some of the requirements of IFRS 7, Financial Instruments: Disclosures. The objective of IFRS 9 is to establish principles for the financial reporting of financial assets and financial liabilities that will present relevant and useful information to users of financial statements for their assessment of the amounts, timing and uncertainty of an entity's future cash flows. The IASB has determined the revised effective date for IFRS 9 will be for annual periods beginning on or after January 1, 2018.

- IFRS 16 Leases

  On January 13, 2016, the International Accounting Standards Board published a new standard, IFRS 16, Leases, eliminating the current dual accounting model for lessees, which distinguishes between on balance sheet finance leases and off-balance sheet operating leases. Under the new standard, a lease becomes an on-balance sheet liability that attracts interest, together with a new right-of-use asset. In addition, lessees will recognize a front-loaded pattern of expense for most leases, even when cash rentals are constant. IFRS 16 is effective for annual periods beginning on or after January 1, 2019, with earlier adoption permitted. The Company intends to adopt IFRS 16 in its financial statements for the annual period beginning January 1, 2019. The extent of the impact of adoption of IFRS 16 has not yet been determined.

4. CRITICAL ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS

The preparation of the interim financial statements in conformity with IFRS, requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Critical accounting estimates and assumptions

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

(Expressed in Canadian dollars)

4. CRITICAL ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS - CONTINUED

Deferred taxes

The Company recognizes the deferred tax benefit related to deferred tax assets to the extent recovery is probable. Assessing the recoverability of deferred tax assets requires management to make significant estimates of future taxable profit. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods from deferred tax assets.

Share-based payment transactions

The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grants. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the share options, volatility and dividend yield and making assumptions about them.

Critical judgments in applying the Company's accounting policies

Critical judgments that management has made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognized in the financial statements are limited to management's assessment of the Company's ability to continue as a going concern (Note 1).

5. RELATED PARTIES TRANSACTION

Amounts due from related parties

	September 30, 2017	**December 31, 2016**
	$	**$**
Amounts owing to CFO of the Company (a)	-	2,625
Amounts owing to a director of the Company (b)	-	825
Zhongyi Financial Investment Consultants (Shenzhen) Ltd. (c)	16,500	16,500
	16,500	19,950

(a) Balance is related to payable to current CFO for her consulting service and reimbursement of expenses.
(b) Balance is related to payable to current Director for his directorship service.
(c) Balance consists of rental fees due to Zhongyi Financial Investment Consultants (Shenzhen) Ltd. ("Zhongyi") which the CEO of the Company is also part of the senior management team . In September 2014, the Company entered into an office rental agreement with Zhongyi for $5,500 per month.

Amounts owing to the CFO, director and Zhongyi are unsecured, non-interest bearing and without fixed repayment terms.

Related party transactions

Compensation of key management personnel

The Company has identified its directors and key officers, including the Chief Executive Officer and Chief Financial Officer, as its key management personnel. No post-employment benefits, other long-term benefits and termination benefits were made during the nine months ended September 30, 2017 and 2016.

(Expressed in Canadian dollars)

5. RELATED PARTIES TRANSACTION - CONTINUED

The remuneration of directors and officers comprising key management personnel during the nine months ended September 30, 2017 and 2016 was as follows:

	September 30, 2017	September 30, 2016
	$	$
Consulting fees incurred to officers	67,500	67,500
Director fees	6,600	6,600
Share-based payments	543	1,793

In September 2014, the Company entered into an office rental agreement with Zhongyi for $5,500 per month. For the nine months ended September 30, 2017, there was $49,500 rental expense under the agreement incurred (September 30, 2016 – $49,500).

On May 18, 2017, the Company closed a non-brokered private placement financing of 1,000,000 common shares of the Company (each, a "Share"), at $0.05 per Share for proceeds of $50,000 (the "Private Placement") from the Company's CEO. The CEO previously had beneficial ownership of, and control and direction over, 4,275,000 common shares of the Company and, pursuant to the Private Placement acquired an additional 1,000,000 resulting in beneficial ownership of, and control and direction over, an aggregate total of 5,275,000 common shares of the Company, representing approximately 24.91% of the total issued and outstanding common shares of the Company.

The above transactions were entered into in the ordinary course of business and recorded at their exchange amounts being the amounts agreed upon by the related parties.

6. CAPITAL MANAGEMENT

The primary objective of managing the Company's capital is to ensure there is sufficient available capital to support the Company's ongoing operation and ensure the Company remains in a sound financial position. As of September 30, 2017, the Company's capital structure consists of share capital of $2,175,070 (December 31, 2016 - $1,881,741). As of September 30, 2017, the Company had a deficit of $2,031,739 (December 31, 2016 - $1,835,800).

The directors of the Company review the capital structure from time to time. As part of this review, the directors considered the cost of capital and the risks associate with the capital structure. The Company is not subject to any externally imposed capital requirements.

7. FINANCIAL INSTRUMENTS

Fair value

The fair value of a financial instrument is the amount of consideration that would be agreed upon in an arm's length transaction between willing parties.

The fair values of cash and cash equivalents, trade payables and accrued liabilities, and due to related parties approximates their carrying value due to their short term maturities.

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

7. FINANCIAL INSTRUMENTS - CONTINUED

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities
Level 2 – inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
Level 3 – inputs that are not based on observable market data.

The fair value of cash and cash equivalents is based on level 1 inputs of the fair value hierarchy.

Financial risk factors

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

(a) Credit Risk

Financial instruments that potentially subject the Company to credit risk consist primarily of cash held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The credit risk on cash is limited because the Company banks with a large international bank with solid credit ratings.

(b) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages all liquidity risk through maintaining sufficient working capital through daily monitoring of controls, cash and cash equivalents balance and operating results. The financial liabilities consisting of trades payables and accrued liabilities are expected to be settled within three months.

8. SHARE CAPITAL

Capital stock

The Company's common shares have no par value and the authorized share capital is composed of 77,000,000 common shares.

On March 6, 2017, the Company completed the Private Placement for aggregate gross proceeds of $245,000. The Private Placement consisted of 4,900,000 common shares of the Company (each, a “Share”), at $0.05 per Share. All of the Shares issued pursuant to the Private Placement are subject to a hold period expiring on July 7, 2017.

On May 18, 2017, the Company closed its non-brokered private placement financing of 1,000,000 common shares of the Company (each, a “Share”), at $0.05 per Share for proceeds of $50,000 (the “Private Placement”). All of the Shares issued pursuant to the Private Placement are subject to a restricted period of four months and one day from the date of closing.

Share capital outstanding at September 30, 2017 was 21,174,230 common shares (December 31, 2016 – 15,274,230)

Escrow shares

As at September 30, 2017, the Company has nil of its shares held in escrow (December 31, 2016 - nil).

(Expressed in Canadian dollars)

8. SHARE CAPITAL - CONTINUED

Stock options

The Company has adopted an incentive stock option plan which provides that the directors of the Company may from time to time, in their discretion, and in accordance with the Exchange requirements, grant to directors, officers, employees and technical consultants to the Company, nontransferable options to purchase common shares, provided that the number of common shares reserved for issue will not exceed 10% of the number of the outstanding common shares.

Such options will be exercisable for a period of up to five years after the date of grant thereof. The number of common shares reserved for issue to any individual director or officer will not exceed 5% of the number of then outstanding common shares and the number of common shares reserved for issue to all technical consultants will not exceed 2% of the number of then outstanding common shares. Options may be exercised the greater of 12 months after completion of the Qualifying Transaction and 90 days following cessation of the optionee's position with the Company, provided that if the cessation of office, directorship, or technical consulting arrangement was by reason of death, the option may be exercised within a maximum period of one year after such death, subject to the expiry date of such option.

(a) Directors' and officers' options

As at September 30, 2017, the Company has stock options outstanding to directors and officers to acquire an aggregate of 200,000 common shares summarized as follows:

	Number of Options	Exercise Price	Expiry Date
Outstanding, December 31, 2014	400,000	$0.12	
Cancelled on April 12, 2015	(50,000)	0.13	May 24, 2018
Cancelled on April 12, 2015	(50,000)	0.10	August 6, 2015
Expired on August 6, 2015	(100,000)	0.10	August 6, 2015
Outstanding, September 30, 2017 and December 31, 2016	200,000	$0.13	May 24, 2018

On May 24, 2013, the Company granted an aggregate of 250,000 options to directors and officers of the Company at an exercise price of $0.13 per share for a period of 60 months. All of the options were vested equally over a four year period (25% on each of the 1st to 4th anniversary dates of grant) and are exercisable in accordance with the terms of the Company's Stock Option Plan.

The fair value of the options at the time of grant using the Black-Scholes Option Pricing Model was $0.11 per option assuming a volatility of 132%, a risk free interest rate of 1.37%, an expected life of 5 years and an expected dividend rate of 0%. The expected volatility assumptions have been developed taking into consideration of historical and implied volatility of the company. During the nine months ended September 30, 2017, the Company recognized share-based payment of $543 related to these options (2016 - $1,793).

The options outstanding at September 30, 2017 have an exercise price $0.13 (December 31, 2016 - $0.13) and a weighted average remaining contractual life of 0.65 years (December 31, 2016 - 1.40 years). There are 200,000 options exercisable at September 30, 2017 (December 31, 2016 - 150,000).

9. SUBSEQUENT EVENTS

a) Share Consolidation, Continuation and Name Change

Effective November 2, 2017, the Company consolidated all of its issued and outstanding common shares based on a consolidation ratio (2.1174-to-1) that resulted in the reduction of the Company's issued and outstanding common shares to 10,000,100 common shares on a non-diluted basis, continued its legal existence from Alberta in to British Columbia, and changed its name from "Kaiyue International Inc" to "Benchmark Botanics Inc."

b) Reverse Takeover Transaction

Further to its news releases dated August 3, 2017 and October 27, 2017, the Company completed the acquisition of all of the issued and outstanding shares of Potanicals Green Growers Inc. ("Potanicals") (the "Transaction") on November 2, 2017.

Terms of Transaction

In consideration for acquiring all of the issued and outstanding shares of Potanicals (the "Potanicals Shares"), Benchmark issued an aggregate of 124,186,752 common shares (the "Benchmark Shares") to the Potanicals shareholders, on the post-consolidation basis of 4.5 Benchmark Shares for each issued and outstanding Potanicals Share, which resulted in Potanicals becoming a wholly-owned subsidiary of the Company. Upon completion of the Transaction, the Company's business has changed from mining to the licensed production of marijuana under the Access to Cannabis for Medical Purposes Regulations ("ACMPR").

On closing of the Transaction, a total of 134,186,852 common shares of Benchmark are issued and outstanding, plus 94,456 stock options to purchase post-consolidated common shares of Benchmark at a price of $0.275 per common share (the "Benchmark Options"). Following closing of the Transaction, the outstanding Benchmark Options remain in effect until they are exercised or expire pursuant to the Company's stock option plan.

Listing of Benchmark's Shares on the CSE

On November 1, 2017, prior to completion of the Transaction, the Company delisted its common shares from the TSX Venture Exchange. On November 3, 2017, Benchmark's common shares commenced trading on the Canadian Securities Exchange (the "CSE") under the symbol "BBT".

Completion of Potanicals Private Placement

Also on November 2, 2017, Potanicals completed a private placement of 5,855,555 Potanicals Shares at a price of $0.90 per Potanicals Share to raise gross proceeds of $5,270,000 (the "Private Placement"). Immediately following closing of the Private Placement, Benchmark completed the Transaction effective November 2, 2017.

Business of Benchmark

The business of Benchmark is now the business of Potanicals effective as of completion of the Transaction. Potanicals was incorporated under the British Columbia *Business Corporations Act* in 2014 to capitalize on the significant opportunities in the medical marijuana market in Canada and overseas. Potanicals has built a 12,700 square foot production facility in Peachland, British Columbia to plant, grow and cultivate high-quality medical-grade marijuana using advanced and proprietary cultivation methods. On October 13, 2017, Potanicals received its license to produce marijuana under the *Access to Cannabis for Medical Purposes Regulations* ("ACMPR").

The primary specialized skill and knowledge requirement for success as a Licensed Producer of medicinal marijuana relates to cultivating the product. The Peachland facility is equipped with cutting-edge technologies that will enable efficient and reliable production of medical marijuana with harvest available on a bi-monthly basis. Prior to closing of the Transaction, Potanicals spent $4.68 million building the facility and implementing its business plan.

9. SUBSEQUENT EVENTS - CONTINUED

For more information about the business of Benchmark and Potanicals, refer to the Form 2A Listing Statement available to the public under the Company's profile on www.sedar.com SEDAR and the CSE website.

Management of Benchmark

Prior to closing of the Transaction, all of the Company's current directors and officers resigned. The board of directors and senior officers of Benchmark now consists of: Ping (Johnson) Zhang, Chief Executive Officer and director; Claude (Cliff) Stowell, Chief Operating Officer and director; Peter R. Hughes, director; George Dorin, director; Haifeng Liu, director; and Richard (Rick) Lee, Chief Financial Officer. For more information regarding the directors and officers, refer to the Form 2A Listing Statement available to the public under the Company's profile on www.sedar.com SEDAR and the CSE website.